Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06573320
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-23
Brief Title:
Effect of Exercise on Clinical Symptoms Cognitive Performance and Quality of Life in Schizophrenia Patients Treated With Clozapine
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Investigating the Effect of Exercise on Clinical Symptoms Cognitive Performance and Quality of Life in Schizophrenia Patients Treated With Clozapine
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This prospective study aims to investigate the effects of exercise on clinical symptoms cognitive performance and quality of life in schizophrenia patients treated with Clozapine
Detailed Description:
The first developed atypical antipsychotic is clozapine Its efficacy has been demonstrated in individuals with schizophrenia who have insufficient response to other antipsychotic therapies nonetheless its adverse effect profile is extensive Among the antipsychotic medications now available clozapine is not utilized as a first-line therapy because of major side effects such agranulocytosis Increased salivation sleepiness weight gain changes in blood pressure sometimes an increase sometimes a drop elevated heart rate dizziness exhaustion constipation fever and nocturnal enuresis are common adverse effects of clozapine usage
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None